Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers

BLOOD ADVANCES

ELSEVIER

1. ASH (Washington, DC)
2. National Cancer Institute, National Institutes of Health [U24CA233032]